Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01149850 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
A Phase 2 study of Glioblastoma and Gliosarcoma, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 3
- Study locations
NCT01149850 is a Phase 2 study of Glioblastoma and Gliosarcoma that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 50 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (54% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT01149850, a Phase 2 study of Glioblastoma and Gliosarcoma, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 3
- Study locations
Study Summary
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as temozolomide, also work in different ways to kill tumor cells or stop them from growing. Giving bevacizumab together with temozolomide may be a better way to block tumor growth. PURPOSE: This phase II trial is studying how well giving bevacizumab and temozolomide together works in treating older patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
Conditions Studied
Interventions
- GENETIC microarray analysis
- OTHER laboratory biomarker analysis
- DRUG temozolomide
- OTHER immunohistochemistry staining method
- BIOLOGICAL bevacizumab
Study Locations (3)
California
- Kaiser Foundation Hospital - Los Angeles
- University of California, Los Angeles - Los Angeles
- Kaiser Permanente at San Diego - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2010-04-28 |
| Est. Completion | 2023-12-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01149850
The ClinicalTrials.gov registry entry for NCT01149850 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (54% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Glioblastoma appearing as the primary indexed condition, and to 5 interventions - of which microarray analysis is the first listed.
NCT01149850 reports 3 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01149850 about?
NCT01149850 is a clinical study titled "Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma". RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as temozolomide, also work...
What is the current status of trial NCT01149850?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2010-04-28. Estimated completion is 2023-12-08.
What conditions does trial NCT01149850 study?
This clinical trial studies the following conditions: Glioblastoma, Gliosarcoma, Giant Cell Glioblastoma.
What interventions are being tested in trial NCT01149850?
The interventions under investigation include: microarray analysis (GENETIC), laboratory biomarker analysis (OTHER), temozolomide (DRUG), immunohistochemistry staining method (OTHER), bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01149850?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01149850 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.